MedPath

The Glycemic Response Elicited by Beta-glucans of Different Physical Properties and Form

Not Applicable
Completed
Conditions
Type 2 Diabetes
Interventions
Dietary Supplement: oat beta-glucan
Dietary Supplement: Placebo
Registration Number
NCT01610518
Lead Sponsor
Guelph Food Research Centre
Brief Summary

The ability of oat β-glucan to lower postprandial glycemic responses has been attributed to the viscosity of the solution in which the fibre is solubilized. To our knowledge, no studies have investigated the effect of β-glucan solutions on glycemic response when concentration, and thus viscosity, is varied by changing the solution volume but not the β-glucan dose. Therefore, the investigators will test the effects of altering β-glucan solution viscosity by altering solution volume at a fixed amount of β-glucan fibre.

Detailed Description

The ability of β-glucan to lower postprandial glycemic responses has been attributed to the viscosity of the solution in which the fibre is solubilized. It has been demonstrated that the viscosity of a β-glucan solution increases with the molecular weight (MW) of β-glucan polymers, as well as the dose or concentration (C) of those polymers in solution. Numerous studies have shown that glycemic response-lowering is strengthened when the C of a β-glucan solution of fixed liquid volume is increased by increasing β-glucan dose. However, the C of a β-glucan solution depends on not only the amount of fibre present but also on the solution volume. To our knowledge, no studies have investigated the effect of β-glucan solutions on glycemic response when C, and thus viscosity, is varied by changing the solution volume but not the β-glucan dose. Therefore, the investigators will test the effects of altering β-glucan solution viscosity by altering solution volume at a fixed amount of β-glucan fibre. Knowing how to incorporate β-glucan into solution so that its physiological benefits are preserved will assist in the development of β-glucan-containing functional foods.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • healthy men and women
Exclusion Criteria
  • BMI greater than or equal to 35
  • known to have diabetes, HIV, hepatitis or a heart condition
  • use of medications or having a condition which may harm the subjects
  • use of medication which may affect the study results

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
250 mL medium viscosityoat beta-glucan250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
600 mL low viscosityoat beta-glucan600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
250 mL high viscosityoat beta-glucan250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
600 mL medium viscosityoat beta-glucan600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
250mL controlPlacebo250 mL beverage containing 50g glucose
600mL controlPlacebo600mL beverage containing 50g glucose
Primary Outcome Measures
NameTimeMethod
postprandial blood glucose2 h

Two fasting blood samples spaced 5 minutes apart (-5 min and 0 min) were collected by finger-prick using a monoejector lancet device. Immediately following the collection of the second blood sample, subjects consumed a test solution and 250mL of a beverage of their choice (water, tea or coffee with milk and/ or artificial sweetener aspartame). Subjects received the same beverage and volume of that beverage for each test in the study. Additional finger-prick blood samples were taken at 10, 20, 30, 40, 50, 60, 90 and 120 minutes after the start of the meal.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

GILabs

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath